GRANDE PHARMACIE DE LA GARE : revenue, balance sheet and financial ratios

GRANDE PHARMACIE DE LA GARE is a French company founded 21 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in GARGES-LES-GONESSE (95140), this company of category PME shows in 2019 a revenue of 1.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - GRANDE PHARMACIE DE LA GARE (SIREN 479330110)
Indicator 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue N/C N/C N/C N/C 1 393 031 € 1 544 089 € 1 483 408 € 1 354 296 € 1 157 055 € 1 210 057 € 1 535 278 €
Net income 46 216 € 110 157 € 84 896 € 62 647 € 18 684 € 55 264 € 60 520 € 38 091 € 50 659 € -83 060 € -94 229 €
EBITDA N/C N/C N/C N/C 31 012 € 63 915 € 59 303 € 9 944 € -577 € -54 293 € -79 147 €
Net margin N/C N/C N/C N/C 1.3% 3.6% 4.1% 2.8% 4.4% -6.9% -6.1%

Revenue and income statement

In 2023, GRANDE PHARMACIE DE LA GARE generates positive net income of 46 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

46 216 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 51%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.03%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

51.096%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

25.3%

Solvency indicators evolution
GRANDE PHARMACIE DE LA GARE

Sector positioning

Debt ratio
0.03 2023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Excellent

In 2023, the debt ratio of GRANDE PHARMACIE DE LA GARE (0.03) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
51.1% 2023
2021
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Good +7 pts over 3 years

In 2023, the financial autonomy of GRANDE PHARMACIE DE LA GARE (51.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 55.09. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

55.095

Liquidity indicators evolution
GRANDE PHARMACIE DE LA GARE

Sector positioning

Liquidity ratio
55.09 2023
2021
2022
2023
Q1: 135.25
Med: 189.78
Q3: 270.35
Watch

In 2023, the liquidity ratio of GRANDE PHARMACIE DE LA GARE (55.09) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
GRANDE PHARMACIE DE LA GARE

Positioning of GRANDE PHARMACIE DE LA GARE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of GRANDE PHARMACIE DE LA GARE is estimated at 545 324 € (range 331 637€ - 766 603€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
331k€ 545k€ 766k€
545 324 € Range: 331 637€ - 766 603€
NAF 5 année 2023

Valuation method used

Net Income Multiple
46 216 € × 11.8x = 545 325 €
Range: 331 638€ - 766 604€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare GRANDE PHARMACIE DE LA GARE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about GRANDE PHARMACIE DE LA GARE

What is the revenue of GRANDE PHARMACIE DE LA GARE ?

The revenue of GRANDE PHARMACIE DE LA GARE in 2019 is 1.4 M€.

Is GRANDE PHARMACIE DE LA GARE profitable?

Yes, GRANDE PHARMACIE DE LA GARE generated a net profit of 46 k€ in 2023.

Where is the headquarters of GRANDE PHARMACIE DE LA GARE ?

The headquarters of GRANDE PHARMACIE DE LA GARE is located in GARGES-LES-GONESSE (95140), in the department Val-d'Oise.

Where to find the tax return of GRANDE PHARMACIE DE LA GARE ?

The tax return of GRANDE PHARMACIE DE LA GARE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does GRANDE PHARMACIE DE LA GARE operate?

GRANDE PHARMACIE DE LA GARE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.